1. Pal T., Permuth-Wey J., Betts J.A. et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. // Cancer - 2005. -V. 104, N 12. - P. 2807-16.
2. Rooth C. Ovarian cancer: risk factors, treatment and management. //Br J Nurs. - 2013. - V. 22, N 17. - P. S23-30.
3. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность) / под редакцией Каприна А.Д., Старинского В.В., Петровой Г.В. - М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России, - 2017. - 250 с.
4. Ebell M.H., Culp M.B., Radke T.J. A Systematic Review of Symptoms for the Diagnosis of Ovarian Cancer. // Am J Prev Med. - 2016. - V. 50, N 3. - P. 384-94.
5. NCCN guidelines panel. Epithelial Ovarian Cancer (including Fallopian Tube Cancer and Primary Peritoneal Cancer). Version 1.2016. // published online: https://www.nccn.org/professionals/physician gls/f guidelines.asp#ovarian. - 2016. P. OV1.
6. Stiekema A., Boldingh Q.J., Korse C.M. et al. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin. // Gynecol Oncol. - 2015. - V. 136, N 3. - P. 562-6.
7. Santotoribio J.D., Garcia-de la Torre A., Canavate-Solano C. et al. Cancer antigens 19.9 and 125 as tumor markers in patients with mucinous ovarian tumors. // Eur J Gynaecol Oncol. -2016. - V. 37, N 1. - P. 26-9.
8. Colombo N., Peiretti M., Garbi A. et al. Non-Epithelial Ovarian Cancer: ESMO Clinical Practice Guidelines. // Ann Oncol. - 2012. V. 23 (Suppl 7). - P. vii20-vii26.
9. Ledermann J. A., Raja F. A., Fotopoulou C. et al. Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: ESMO Clinical Practice Guidelines. // Ann Oncol. - 2013. -V. 24 (Suppl 6). - P. vi24-vi32.
10. Sankaranarayanan R. Screening for cancer in low- and middle-income countries. // Ann Glob Health. - 2014. - V. 80, N 5. - P. 412-7
11. Yadav B.S., Sharma S.C., Robin T.P. Synchronous primary carcinoma of breast and ovary versus ovarian metastases. // Semin Oncol. - 2015. - V. 42, N 2. - P. e13-24.
12. Stuart G., Kitchener H., Bacon M. et al. 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Int J Gynecol Cancer 2011;21: 750Y755
13. Trimbos J.B., Parmar M., Vergote I. et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003 Jan 15;95(2):105-12.
14. Vergote I., Trope C.G., Amant F. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. // N Engl J Med. - 2010. - V. 363. - P. 943-53.
15. Young R.C., Walton L.A., Ellenberg S.S. et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. // N Engl J Med. - 1990. - V. 322. - P. 1021-7.
16. Young R.C., Brady M.F., Nieberg R.M. et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin—A Gynecologic Oncology Group study. // J Clin Oncol 2003. V 21, N 23. P. 4350-5.
17. Bolis G., Colombo N., Pecorelli S. et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). GICOG: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. // Ann Oncol. - 1995. - V. 6, N 9. - P. 887-93
18. Oza A.M., Cook A.D., Pfisterer J. et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. // The Lancet Oncology. 2015. - V. 16, N 8. - P. 928-936.
19. Gershenson D., Bodurka D., Coleman R. et al. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum // J Clin Oncol. - 2017. In print
20. Rustin G.J., Vergote .I, Eisenhauer E. et al. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) // Int J Gynecol Cancer. - 2011. V 21, N 2. P. 419-23.
21. Harter P., du Bois A., Hahmann M. et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. // Ann Surg Oncol. - 2006. - V. 13, N 12. - P. 1702-10.
22. Harter P., Sehouli J., Reuss A. et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. // Int J Gynecol Cancer. - 2011. - V. 21, N 2. - P. 289-95.
23. Rustin G.J., van der Burg M.E., Griffin C.L. et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. // Lancet. - 2010. V. 376, N 9747. - P. 1155-63
24. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
25. Gore M, Fryatt I, Wiltshaw E, Dawson T: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these components. Gynecol Oncol 36:207-211, 1990
26. Mahner S., Meier W., du Bois A. et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Eur J Cancer. 2015 Feb;51(3):352-8
27. The ICON and AGO Collaborators Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial // Lancet. - 2003. - V. 361. - P. 2099-106
28. Hoskins P.J., Le N. Identifying patients unlikely to benefit from further chemotherapy: A descriptive study of outcome at each relapse in ovarian cancer // Gynecologic Oncology. 2005. -V. 97. - P. 862 - 869